In a filing, Intra-Cellular Therapies Inc revealed its Chairman and CEO Mates Sharon unloaded Company’s shares for reported $4.38 million on Dec 04 ’24. In the deal valued at $85.80 per share,51,000 shares were sold. As a result of this transaction, Mates Sharon now holds 1,070,329 shares worth roughly $137.61 million.
Then, Mates Sharon sold 51,697 shares, generating $4,346,842 in total proceeds. Upon selling the shares at $84.08, the Chairman and CEO now owns 1,070,329 shares.
Before that, Mates Sharon bought 51,697 shares. Intra-Cellular Therapies Inc shares valued at $4,343,616 were divested by the Officer at a price of $84.02 per share.
Mizuho downgraded its Intra-Cellular Therapies Inc [ITCI] rating to a Neutral from a an Outperform in a research note published on February 24, 2025; the price target was decreased to $132 from $140. A number of analysts have revised their coverage, including Canaccord Genuity’s analysts, who decreased its forecast for the stock in late January from “a Buy” to “a Hold”. Piper Sandler also remained covering ITCI and has increased its forecast on September 06, 2024 with a “an Overweight” recommendation from previously “Neutral” rating. Robert W. Baird started covering the stock on January 03, 2024. It rated ITCI as “an Outperform”.
Price Performance Review of ITCI
On Friday, Intra-Cellular Therapies Inc [NASDAQ:ITCI] saw its stock fall -0.02% to $128.57. Over the last five days, the stock has gained 0.59%. Intra-Cellular Therapies Inc shares have risen nearly 53.94% since the year began. Nevertheless, the stocks have risen 75.45% over the past one year. While a 52-week high of $128.77 was reached on 02/21/25, a 52-week low of $62.78 was recorded on 01/07/25. SMA at 50 days reached $109.40, while 200 days put it at $84.03.
Levels Of Support And Resistance For ITCI Stock
The 24-hour chart illustrates a support level at 128.49, which if violated will result in even more drops to 128.42. On the upside, there is a resistance level at 128.68. A further resistance level may holdings at 128.80. The Relative Strength Index (RSI) on the 14-day chart is 83.63, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.79, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 10.58%. Stochastics %K at 89.42% indicates the stock is a selling.
The most recent change occurred on December 11, 2023 when TD Cowen began covering the stock and recommended ‘”an Outperform”‘ rating along with a $75 price target.
